Benevolentai Acquires Advanced Cambridge Research Facility to Accelerate Its AI-Enabled Drug Development
Benevolentai Acquires Advanced Cambridge Research Facility to Accelerate Its AI-Enabled Drug Development Acquisition creates first AI company capable of covering entire drug development process from drug discovery to clinical development PR Newswire LONDON, February 22, 2018 LONDON , February 22, 2018 /PRNewswire/ — Cambrid ge research facility will advance BenevolentAI drug programmes into the clinic more quickly and at a much larger scale BenevolentAI, one of the world’s largest private AI companies, today announced that it has acquired a state-of-the-art drug discovery and development facility on the Babraham Research Campus in Cambridge (UK) for an undisclosed sum. The acquisition creates a unique AI-enabled research centre that can radically reduce the time it takes for drug candidates to enter clinical testing and deliver significantly higher success rates in treating or curing disease. The acquisition marks the first time an AI company will be able to work across the entire drug development process ‘end-to-end’ from drug discovery to late stage clinical development […]